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RESULTSINTRODUCTION
EXPERIMENTAL APPROACHES
 Cyclic AMP levels peaked within 30mins of treprostinil treatment, but surprising dropped within an hour to almost the 
basal value. We hypothesize this is due to the higher activity of the phosphodiesterase enzymes which break down cAMP 
(PDE 1, 3, 4).
 High activity of PDE3 was assumed as we observed that the peak cAMP level was higher with the combination of 
treprostinil and the PDE3 inhibitor, cilostazole than with treprostinil alone and elevation was significantly sustained for up to 
24 hrs compared. 
 High activity of PDE3 might explain in part the ineffectiveness of prostacyclins (PGI2) in long-term therapy and we 
propose that a PDE3 inhibitor might potentiate PGI2 effects in PAH. 
 In our study we demonstrated that cilostazole could significantly potentiate cAMP levels, antiproliferative and relaxation 
effects of treprostinil suggesting that this combination could be clinically beneficial for treating  PAH. 
 Cilostazol is already in clinical use for intermittent claudication (peripheral vascular occlusive disease) where it increases 
exercise tolerance and favorably modifies the plasma lipid profile, suggesting additional beneficial effects in diseases 
associated with atherosclerosis2 and could be possibly a new therapeutic agent for IPAH.
SUMMARY AND CONCLUSION
Phosphodiesterase - type 3 inhibitor cilostazole potentiates cAMP generation and antiproliferative effects of 
treprostinil in pulmonary arterial smooth muscle cells from patients with  pulmonary hypertension
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Distal pulmonary arterial smooth muscle cells (PASMCs) 
isolated from the lungs of patients (n=6) suffering from 
idiopathic pulmonary arterial hypertension (IPAH) and rat 
tail artery were used for these experiments. 
• cAMP measurement : Cyclic AMP levels were assessed 
in cultured human PASMCs using ELISA kit from R&D 
systems (Abingdon, UK). Cells were grown in DMEM/F12 
containing 10% FBS  to 70% confluence before being 
stimulated for varying times with treprostinil (TREP; 1 
µM) or in combination with 1 µM cilostasole (PDE3 
inhibitor), given 1 hr prior to treprostinil. Results are 
expressed as pmol of cyclic AMP per mg of total protein. 
• Cell proliferation assay :  Human PASMCs from IPAH 
patients were grown for 24 hrs in DMEM/F12 containing 
10 % FBS and starved for 48 hr in media alone. Cells 
were then stimulated with 10% FBS ± treprostinil (1μM), 
cilostazole (1 μM or 10 μM) or in combination. Cells were 
counted after 4 days using ADAM-MC cell counter 
(Korea).
• Myography : To assess whether PDE3 inhibition could 
potentiate relaxation to treprostinil, rat tail arteries 
(~2mm long)  were mounted onto an isometric myograph  
(500A JP Trading, Denmark). After a normalisation 
procedure vessels were contracted with 1 µM 
phenylephrine followed by sequential application of 
increasing doses of treprostinil ± cilostazole (10 μM). 
The prostacyclin class of drugs are used to treat 
pulmonary arterial hypertension, and while evidence 
suggests they improve survival, these agents 
eventually stop working. Thus ways are being sort to 
improve their clinical efficacy. We hypothesise that 
prostacyclin action could be enhanced by inhibition of 
phosphodiesterase type 3 (PDE3), a major regulator of 
cyclic AMP levels in the lung, whose activity appears 
increased in pulmonary hypertension.1
Figure 4. Cilostazole potentiates the relaxation response  
of treprostinil.
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Figure 2. Effect of treprostinil on cAMP generation (in presence  & absence  of 1µM 
cilostazole ) in distal human PASMCs derived  from IPAH lungs
Figure  3. Cilostazole potentiates the  anti-proliferative 
effects of treprostinil in distal human PASMCs derived  
from IPAH lungs
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Figure 1. Cyclic AMP levels in human PASMCs in the 
absence and presence of treprostinil (1uM; TREP).  Levels 
peaked within 30min and dropped  back to control thereafter. 
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